Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.
2016
e19052Background: Duvelisib (IPI-145), an oral dual inhibitor of PI3K-δ and -γ, is being evaluated as an oral therapeutic for hematologic malignancies as a monotherapy or in combination with anti-C...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
5
Citations
NaN
KQI